

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 30 January 2021

Situation Report No. 223 - Kingdom of Bahrain  
31<sup>th</sup> of January, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	101,561,219	2,196,944	5,648,515	133,485
<b>New</b>	2,556,190 in 5 days	69,636 in 5 days	117,690 in 5 days	2,135 in 5 days

## Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
<b>Total</b>	102,626	98,160	372	4,094	25	2,701,085
<b>New</b>	2,369 in 5 days	1,399 in 5 days	3 in 5 days	-	-	63,206 in 5 days

## HIGHLIGHTS

- The mortality were: a 53 and 64 years old male expatriate and a 84 years old male Bahraini Citizen.
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 30 January 2021 is 170,433.
- HRH the Crown Prince and Prime Minister addressed a national message on COVID-19 update.
- Undersecretary Ministry of Health addressed the public "don't leave home unless necessary", calling on all to limit social interactions to avoid complacency and further spread of the virus.
- Ministry of Education announced three weeks suspension of in-person attendance at all schools starting from January 31 2021.
- Ministry of Industry, Commerce and Tourism announced suspension of restaurants indoor dining while continuing outdoor dining services for three weeks.
- Ministry of Labour and Social Development announced three weeks suspension of in-person attendance at all at rehabilitation centers, nurseries, and private training centers and institutes starting from January 31 2021.
- Bahrain received the first batch of Covishield - AstraZeneca Vaccine from India; and registration for its administration is now open.
- Hotels are to meet stricter criteria (in compliance with COVID-19 protocols) from January 31 2021 for hosting weddings, exhibitions, business meetings and conferences.
- A cluster of 25 COVID-19 cases in four different locations was caused by direct contacts with a 38-year-old man who tested positive for Coronavirus.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Draft landscape of COVID-19 candidate vaccines; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic; see link below.
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020; see link below.


## IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6449a76\\_4](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6449a76_4)
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies: <https://www.who.int/news/item/18-12-2020-cvwa-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/25vds0r>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: <https://www.who.int/publications/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay: <https://bit.ly/2R0JVF>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2J0wXWQ>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-HEE\\_assessment-products-2021.1](https://www.who.int/publications/item/WHO-2019-nCoV-HEE_assessment-products-2021.1)
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/item/9789240017467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/1066333753>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: [https://www.who.int/publications/item/WHO-2019-nCoV-Policy\\_Brief-EUD\\_placebo-controlled\\_vaccine\\_trials-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-Policy_Brief-EUD_placebo-controlled_vaccine_trials-2020.1)
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based\\_International\\_travel\\_assessment\\_tool-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based_International_travel_assessment_tool-2020.1)
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/item/18-12-2020-cvwa-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/item/9789240018440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: [https://www.who.int/publications/item/WHO-2019-nCoV-vaccines-SAGE\\_recommendation-BNT162b2-2021.1](https://www.who.int/publications/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1)
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Draft landscape of COVID-19 candidate vaccines: <https://www.who.int/publications/item/draft-landscape-of-covid-19-candidate-vaccines>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: [https://www.who.int/publications/item/WHO-2019-nCoV-essential\\_health\\_services-monitoring-2021.1](https://www.who.int/publications/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1)
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: <https://www.who.int/publications/item/background-document-on-mrna-vaccine-bnt162b2-pfizer-biontech-against-covid-19>
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum: <https://www.who.int/news/item/16-01-2021-scientists-tackle-vaccine-safety-eficacy-and-access-at-global-r-d-forum>
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines: <https://www.who.int/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines>
- WHO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic: <https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-2005-emergency-committee-regarding-the-coronavirus-disease-covid-19-pandemic>
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020: <https://www.who.int/publications/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>


## IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAI5@health.gov.bh](mailto:NAI5@health.gov.bh)
- International Health Regulations focal person is Dr. Kubra Salman, email: [knasser@health.gov.bh](mailto:knasser@health.gov.bh)

Number of New Cases



Total Number of Cases



Number of New Deaths

